<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>煜森资本 | wechat-feeds</title><link>http://MzI3MzcxODkyNQ.favicon.privacyhide.com/favicon.ico</link><description>医疗健康投融资平台  科学家创业平台</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 09 Jun 2021 11:46:35 +0800</pubDate><image><url>http://MzI3MzcxODkyNQ.favicon.privacyhide.com/favicon.ico</url><title>煜森资本 | wechat-feeds</title><link>http://MzI3MzcxODkyNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>西藏，真能洗涤你的灵魂吗？</title><link>https://mp.weixin.qq.com/s/PnGD5Gcby4KRITSqVX82Tg</link><description></description><content:encoded><![CDATA[西藏，真能洗涤你的灵魂吗？]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>治疗肝细胞癌，泽璟制药1类新药多纳非尼正式获批</title><link>https://mp.weixin.qq.com/s/dU8O0-5dncuEqghYXo3JEw</link><description></description><content:encoded><![CDATA[治疗肝细胞癌，泽璟制药1类新药多纳非尼正式获批]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>心源性猝死防治平台维伟思医疗完成A+轮融资，打造“WCD+AED”双中心战略</title><link>https://mp.weixin.qq.com/s/9t40VpTTiS8-qjkC-d3B3Q</link><description></description><content:encoded><![CDATA[心源性猝死防治平台维伟思医疗完成A+轮融资，打造“WCD+AED”双中心战略]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>基点生物成功完成C轮融资，北极光领投</title><link>https://mp.weixin.qq.com/s/jtn3v5bdynDHVmkrICYCjw</link><description></description><content:encoded><![CDATA[基点生物成功完成C轮融资，北极光领投]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>勤浩医药完成超2亿元A轮融资，推进新一代抗肿瘤药的开发</title><link>https://mp.weixin.qq.com/s/-ZbII8INnfH0lLmHdUj9_A</link><description></description><content:encoded><![CDATA[勤浩医药完成超2亿元A轮融资，推进新一代抗肿瘤药的开发]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>一波三折，渤健AD药物终于上市，每年费用5.6万美元</title><link>https://mp.weixin.qq.com/s/iWWiORjdpZe8YjfuGY4aFA</link><description></description><content:encoded><![CDATA[一波三折，渤健AD药物终于上市，每年费用5.6万美元]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>荣昌生物ADC品种即将获批上市 | 肺干细胞新药治疗COPD获批临床...</title><link>https://mp.weixin.qq.com/s/Yk8tVfV3Lq087hgob4GZdw</link><description></description><content:encoded><![CDATA[荣昌生物ADC品种即将获批上市 | 肺干细胞新药治疗COPD获批临床...]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>恒瑞医药64项研究入选ASCO年会，卡瑞利珠单抗力撑“半壁江山”</title><link>https://mp.weixin.qq.com/s/Wg8U20JOosrVEaJdpciMvA</link><description></description><content:encoded><![CDATA[恒瑞医药64项研究入选ASCO年会，卡瑞利珠单抗力撑“半壁江山”]]></content:encoded><pubDate>Wed, 09 Jun 2021 11:40:19 +0800</pubDate></item><item><title>广西！广西！</title><link>https://mp.weixin.qq.com/s/u56fRTLnOMC_n5s8YXqPsA</link><description></description><content:encoded><![CDATA[广西！广西！]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>百济神州递交抗PD-1抗体第7项适应症上市申请，针对MSI-H或dMMR实体瘤！</title><link>https://mp.weixin.qq.com/s/PmD1kifOiZby4j4VxAwTHA</link><description></description><content:encoded><![CDATA[百济神州递交抗PD-1抗体第7项适应症上市申请，针对MSI-H或dMMR实体瘤！]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>鼻咽癌一线治疗！恒瑞医药抗PD-1抗体有望迎来新适应症</title><link>https://mp.weixin.qq.com/s/oWkLDT6ZSPX8WqowezgT-w</link><description></description><content:encoded><![CDATA[鼻咽癌一线治疗！恒瑞医药抗PD-1抗体有望迎来新适应症]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>叮当快药完成新一轮2.2亿美元融资</title><link>https://mp.weixin.qq.com/s/KZX4AeYr-bZWek8wCYUT4A</link><description></description><content:encoded><![CDATA[叮当快药完成新一轮2.2亿美元融资]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>医疗大健康投融资周报</title><link>https://mp.weixin.qq.com/s/BjL4cH67VebrLQI2te_Mgg</link><description></description><content:encoded><![CDATA[医疗大健康投融资周报]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>医疗大数据公司医利捷完成首轮融资，软银中国独家领投</title><link>https://mp.weixin.qq.com/s/jTDYefbB07iAsvz2w67kDA</link><description></description><content:encoded><![CDATA[医疗大数据公司医利捷完成首轮融资，软银中国独家领投]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>亚盛医药Bcl-2抑制剂治疗R/R CLL/SLL最新数据公布：ORR达80%</title><link>https://mp.weixin.qq.com/s/PXNlQejZR_5akcH3qwpUpw</link><description></description><content:encoded><![CDATA[亚盛医药Bcl-2抑制剂治疗R/R CLL/SLL最新数据公布：ORR达80%]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>国产重组凝血因子VIII临床积极 | 强生FcRn抗体国内报IND...</title><link>https://mp.weixin.qq.com/s/alCChVl47K81fgtNABfJ5w</link><description></description><content:encoded><![CDATA[国产重组凝血因子VIII临床积极 | 强生FcRn抗体国内报IND...]]></content:encoded><pubDate>Tue, 08 Jun 2021 11:32:02 +0800</pubDate></item><item><title>12年磨砺今朝亮剑，祝所有高考学子旗开得胜，梦想成真！</title><link>https://mp.weixin.qq.com/s/3N-vxvktHN_485vhqJQ5tA</link><description></description><content:encoded><![CDATA[12年磨砺今朝亮剑，祝所有高考学子旗开得胜，梦想成真！]]></content:encoded><pubDate>Mon, 07 Jun 2021 14:11:41 +0800</pubDate></item><item><title>基于下一代测序技术的新方法可用于新冠病毒大规模检测</title><link>https://mp.weixin.qq.com/s/3WS6XXFi7qirr2odDxL62w</link><description></description><content:encoded><![CDATA[基于下一代测序技术的新方法可用于新冠病毒大规模检测]]></content:encoded><pubDate>Mon, 07 Jun 2021 14:11:41 +0800</pubDate></item><item><title>康黎医学获近亿元Pre-B轮融资，深耕精神科基因检测赛道</title><link>https://mp.weixin.qq.com/s/DearC3HNASs9I_gI1mRQ_A</link><description></description><content:encoded><![CDATA[康黎医学获近亿元Pre-B轮融资，深耕精神科基因检测赛道]]></content:encoded><pubDate>Mon, 07 Jun 2021 14:11:41 +0800</pubDate></item><item><title>极目生物宣布引进FDA批准干眼治疗器械大中华区、韩国及东盟十国独家权益</title><link>https://mp.weixin.qq.com/s/HNlGH3gLY2Xh8qen0ZwfhA</link><description></description><content:encoded><![CDATA[极目生物宣布引进FDA批准干眼治疗器械大中华区、韩国及东盟十国独家权益]]></content:encoded><pubDate>Mon, 07 Jun 2021 14:11:41 +0800</pubDate></item></channel></rss>